ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near London, England, GBR:

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Other: Ofatumumab placebo
Drug: Siponimod

Phase 3

Novartis
Novartis

London, United Kingdom and 73 other locations

The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS...

Enrolling
Primary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Drug: Ixazomib (NINLARO®) capsules / Matching placebo capsules

Phase 1

Queen Mary University of London

London, Greater London, United Kingdom

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

Phase 3

Roche
Roche

London, United Kingdom and 161 other locations

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...

Enrolling
Multiple Sclerosis
Drug: Placebo capsule
Drug: Fingolimod

Phase 3

Novartis
Novartis

London, United Kingdom and 107 other locations

This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple...

Active, not recruiting
Multiple Sclerosis
Clinically Isolated Syndrome
Drug: Ocrelizumab

Phase 4

Roche
Roche

London, United Kingdom and 8 other locations

effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (Qo...

Active, not recruiting
Multiple Sclerosis
Drug: Beta-Interferon
Drug: Methylprednisolone

Phase 3

Genzyme
Genzyme

London, London, City Of, United Kingdom and 20 other locations

Multiple Sclerosis (MS) is a chronic inflammatory \& degenerative disease of the central nervous system (CNS) Recent data ...

Enrolling
Multiple Sclerosis
Clinically Isolated Syndrome of Demyelination
Drug: Tysabri Injectable Product
Drug: Placebo

Phase 2

Queen Mary University of London

London, United Kingdom

and adolescents 10 to 17 years of age with relapsing forms of multiple sclerosis (MS).Secondary Objective:* To assess the ...

Active, not recruiting
Multiple Sclerosis
Drug: Placebo
Drug: Teriflunomide

Phase 3

Genzyme
Genzyme

London, London, City Of, United Kingdom and 54 other locations

with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Other: Ocrelizumab Placebo
Drug: Ocrelizumab

Phase 3

Roche
Roche

London, United Kingdom and 118 other locations

effective and CNS penetrant DMT for patients with relapsing multiple sclerosis (pwRMS) administered in short (8-10 days/year over ...

Enrolling
Advanced Multiple Sclerosis
Progressive Multiple Sclerosis
Drug: Placebo
Drug: Cladribine (MAVENCLAD®)

Phase 2, Phase 3

Queen Mary University of London

London, United Kingdom and 21 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems